BRIEF published on 10/31/2024 at 09:05, 1 year 7 months ago Braidwell LP Crosses Thresholds in DBV Technologies Warrants Actions DBV Technologies Participation Threshold Braidwell LP
BRIEF published on 10/22/2024 at 22:50, 1 year 7 months ago DBV's Viaskin Peanut Patch Secures Regulatory Progress in US and EU FDA Approval DBV Technologies Viaskin Peanut Regulatory Update EMA Guidance
PRESS RELEASE published on 10/22/2024 at 22:45, 1 year 7 months ago DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV Technologies announces positive regulatory updates for Viaskin Peanut Patch in the United States and Europe, aiming for Accelerated Approval for toddlers 1-3 years old Accelerated Approval Regulatory Updates DBV Technologies Viaskin Peanut Patch Toddlers
BRIEF published on 10/18/2024 at 22:35, 1 year 7 months ago DBV Technologies to Engage in ACAAI 2024 Congress DBV Technologies Allergy Treatment Peanut Allergy Viaskin Peanut Patch ACAAI 2024
PRESS RELEASE published on 10/18/2024 at 22:30, 1 year 7 months ago DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies to participate in ACAAI 2024 Congress, presenting on optimal peanut allergy treatment and sponsoring FIT Bowl. Viaskin Peanut patch for food allergies highlighted DBV Technologies Food Allergies Viaskin Peanut Patch ACAAI 2024 Congress Peanut Allergy Treatment
BRIEF published on 10/14/2024 at 22:35, 1 year 8 months ago DBV Technologies Share Capital Status as of September 30, 2024 Share Capital Voting Rights DBV Technologies Euronext Exchanges Listed Shares
BRIEF published on 09/23/2024 at 22:35, 1 year 8 months ago DBV Technologies Completes Screening of Subjects for Phase 3 VITESSE Clinical Trial Clinical Trial Phase 3 DBV Technologies Viaskin Peanut Peanut Allergy
PRESS RELEASE published on 09/23/2024 at 22:30, 1 year 8 months ago DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial DBV Technologies completes screening for VITESSE Phase 3 Clinical Trial evaluating Viaskin Peanut Patch in peanut allergic children ages 4-7. Topline results expected Q4 2025 Clinical Trial DBV Technologies Food Allergies VITESSE Phase 3 Viaskin Peanut Patch
BRIEF published on 09/04/2024 at 22:35, 1 year 9 months ago DBV Technologies to Participate in 26th Annual HC Wainwright Global Investment Conference DBV Technologies Viaskin Food Allergies HC Wainwright Lecture Epicutaneous Immunotherapy
PRESS RELEASE published on 09/04/2024 at 22:30, 1 year 9 months ago DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference DBV Technologies to participate in H.C. Wainwright 26th Annual Global Investment Conference with CEO Daniel Tassé in New York City. Focus on food allergy treatment and immunotherapy Immunotherapy DBV Technologies Food Allergies H.C. Wainwright Conference VIASKIN Patch
Published on 06/13/2026 at 04:50, 2 days 1 hour ago BTU Additional Details Regarding Recent Acquisition
Published on 06/13/2026 at 02:00, 2 days 4 hours ago Battery X Metals Appoints Automotive Industry Professional from Canadian Subsidiary of One of the World's Leading Premium Automobile Manufacturers, Headquartered in Munich, Germany, to its Advisory Board to Advance Commercialization of Its Patent-Pending
Published on 06/12/2026 at 23:15, 2 days 7 hours ago BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/12/2026 at 22:30, 2 days 7 hours ago Fox River Provides Reminder To Vote And Updated Dissent Rights
Published on 06/12/2026 at 15:14, 2 days 15 hours ago Reeflex Solutions Inc. Reports Voting Results From Annual and Special Meeting of Shareholders
Published on 06/15/2026 at 05:45, 42 minutes ago A Robot Sat in the Driver's Seat: THINKCAR and MUCAR Brought AI Diagnostics to 200+ KOLs at the AliExpress Brand+ Summer Party in London
Published on 06/14/2026 at 14:50, 15 hours 37 minutes ago Zug voters say yes to Metalli development plan
Published on 06/14/2026 at 13:30, 16 hours 57 minutes ago Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Published on 06/14/2026 at 10:42, 19 hours 45 minutes ago LightOn Demonstrates the Flexibility of Its OCR Model by Adapting It to Arabic Through Targeted Training.
Published on 06/13/2026 at 08:18, 1 day 22 hours ago EQS-Adhoc: AT&S Austria Technologie & Systemtechnik AG: AT&S expands AI substrate capacity in Kulim and increases outlook for 2026/27
Published on 06/12/2026 at 18:31, 2 days 11 hours ago Share retention commitments (Dutreil agreement)
Published on 06/12/2026 at 09:00, 2 days 21 hours ago Pricing of Green Senior Secured Notes due 2031 by Neoen FINCO PLC
Published on 06/11/2026 at 17:45, 3 days 12 hours ago BAIKOWSKI: Annual General Meeting of June 11, 2026 - Dividend of €0.30 per share, to be paid out on June 30, 2026
